NewsRoom Articles - Page 2 of 231

TuesdayMar 31, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. The significance of the UK designation extends beyond a single program. The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease. A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development…

TuesdayMar 31, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address. Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods. The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs,…

MondayMar 30, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…

FridayMar 27, 2026 10:00 am

Major Discovery Could Reshape Cancer Immunotherapy

Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to scientists. This brake exists on immune cells and scales back their ability to combat cancer, and it acts without any influence from tumor cells. This molecule, dubbed SLAMF6, occurs naturally on fighter immune cells called T-cells. It is an inbuilt weakness on those cells and it shuts off T-cells’ capacity to kill tumor cells. In preclinical trials, the researchers turned off this switch and were able to revive the immune cells’ ability to combat cancer. The study, whose findings were…

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

ThursdayMar 26, 2026 10:00 am

Hackers Linked to Iran Target Another US Health Care Institution

On Tuesday this week, researchers revealed that a group of hackers linked to the Iranian government had targeted another United States medical institution toward the end of February prior to the onset of the current military conflict between the U.S., Israel and Iran. This is the second such attack. This attack is noteworthy because this information comes on the heels of another attack in which Stryker, a medical device firm in America, was targeted and had its data deleted. Handala, a hacktivist group linked to Iran, claimed responsibility for this attack that resulted in about 80,000 systems being deleted. Stryker is currently restoring its systems and the attack has now been contained. It isn’t clear whether other attacks have happened…

ThursdayMar 26, 2026 9:00 am

Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

ETST is focused on compounding pharmacies, telemedicine, and clinical services Vertically integrated model supports recurring, patient-driven revenue The company’s strategy aligns with increased demand for personalized and digital healthcare Earth Science Tech (OTC: ETST) is consolidating on its identity as a leading healthcare holding company, implementing a strategy built on vertical integration across telemedicine, pharmaceuticals, and clinical services. The company’s transitioning from legacy operations highlights a distinct alignment with high-growth segments of the healthcare sector, particularly personalized medicine and digital care delivery (ibn.fm/9lMJg). At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific…

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

TuesdayMar 24, 2026 10:00 am

Misinformation Could Thwart the Potential of Cancer Vaccines

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention. Most people first heard about mRNA vaccines during the Covid-19 pandemic when these vaccines were widely used to bring the pandemic under control. However, misinformation soon spread that these vaccines were not only accelerating cancer rates but also causing cancer to be “turbo-charged.” Social media was awash with stories of “turbo cancer” starting in 2021 and mainstream media caught…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…